New Risk • May 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (HK$260.3m market cap, or US$33.2m). Annonce • May 02
Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, May 22, 2026 Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, May 22, 2026, at 10:00 China Standard Time. Location: 9th floor, block a2, tianda high-tech park, no. 80, the 4th avenue, teda, tianjin, China Reported Earnings • Apr 04
Full year 2025 earnings released Full year 2025 results: Revenue: CN¥523.0m (up 36% from FY 2024). Net loss: CN¥90.8m (loss widened 206% from FY 2024). New Risk • Mar 24
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CN¥135m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (HK$640.2m market cap, or US$81.7m). Annonce • Mar 13
Tianjin TEDA Biomedical Engineering Company Limited to Report Fiscal Year 2025 Results on Mar 31, 2026 Tianjin TEDA Biomedical Engineering Company Limited announced that they will report fiscal year 2025 results on Mar 31, 2026 Annonce • Dec 31
Tianjin TEDA Biomedical Engineering Company Limited Announces Directorate Appointments Tianjin TEDA Biomedical Engineering Company Limited, at the EGM held on 31 December 2025 approved election of Mr. Yang Zeng and Mr. Xia Alan Zhe as an executive Director of the Company for a term of three years, effective from the date of approval by the Shareholders of the Company. The company appointed Mr. Wang Lei as a non-executive Director of the Company for a term of three years, effective from the date of approval by the Shareholders of the Company. The company appointed Mr. Chen Jiang as an independent non-executive Director of the Company for a term of three years, effective from the date of approval by the Shareholders of the Company. New Risk • Nov 26
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: HK$768.2m (US$98.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CN¥135m free cash flow). Minor Risk Market cap is less than US$100m (HK$768.2m market cap, or US$98.8m). Reported Earnings • Aug 31
First half 2025 earnings released First half 2025 results: Revenue: CN¥226.4m (up 7.0% from 1H 2024). Net loss: CN¥6.43m (loss widened 56% from 1H 2024). Annonce • Aug 15
Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2025 Results on Aug 29, 2025 Tianjin TEDA Biomedical Engineering Company Limited announced that they will report first half, 2025 results on Aug 29, 2025 Annonce • Apr 09
Tianjin TEDA Biomedical Engineering Company Limited has filed a Follow-on Equity Offering in the amount of HKD 38.8125 million. Tianjin TEDA Biomedical Engineering Company Limited has filed a Follow-on Equity Offering in the amount of HKD 38.8125 million.
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 103,500,000
Price\Range: HKD 0.375
Transaction Features: Subsequent Direct Listing Reported Earnings • Apr 02
Full year 2024 earnings released: CN¥0.016 loss per share (vs CN¥0.008 loss in FY 2023) Full year 2024 results: CN¥0.016 loss per share (further deteriorated from CN¥0.008 loss in FY 2023). Revenue: CN¥385.5m (down 3.1% from FY 2023). Net loss: CN¥29.6m (loss widened 104% from FY 2023). Over the last 3 years on average, earnings per share has increased by 45% per year whereas the company’s share price has increased by 43% per year. Annonce • Apr 01
Tianjin TEDA Biomedical Engineering Company Limited Announces Re-Designation of He Xin from Executive Director to Non-Executive Director, Effect from 31 March 2025 The board of directors of Tianjin TEDA Biomedical Engineering Company Limited announced that Mr. He Xin ("Mr. He") was re-designated from executive Director to non-executive Director of the Company with effect from 31 March 2025 as he would like to devote more time to his personal developments. Mr. He, aged 55, postgraduate, graduated from Beijing Jiaotong University majoring in Mechanical Engineering. From July 1992 to June 1994, he served as a business manager of the export department of China Railway Import and Export Company under the Ministry of Railway From June 1994 to May 2005, he worked as a secretary of the administrative department of Shenzhen Golden Century Development Company Limited From May 2005 to September 2009, he served as an investment manager of the international department of China Merchants Securities Company Limited. From September 2010 to March 2014, he held a position as a vice president of Beijing Yingguxinye Investment Co. Ltd. From March 2014 to August 2016, he held positions as a director and a general manager of Ningxia Yinggu Industry Company Limited. From August 2016 to present, he has been serving as a general manager of Beijing Yingguxinye Investment Co. Ltd. Mr. He joined the Company in December 2018 and was appointed as executive director of the Company. New Risk • Mar 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Annonce • Mar 12
Tianjin TEDA Biomedical Engineering Company Limited to Report Fiscal Year 2024 Results on Mar 31, 2025 Tianjin TEDA Biomedical Engineering Company Limited announced that they will report fiscal year 2024 results on Mar 31, 2025 Annonce • Feb 20
Tianjin TEDA Biomedical Engineering Company Limited has completed a Follow-on Equity Offering in the amount of HKD 50.9625 million. Tianjin TEDA Biomedical Engineering Company Limited has completed a Follow-on Equity Offering in the amount of HKD 50.9625 million.
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 135,900,000
Price\Range: HKD 0.375
Transaction Features: Subsequent Direct Listing Annonce • Jan 17
Tianjin TEDA Biomedical Engineering Company Limited has filed a Follow-on Equity Offering in the amount of HKD 63.441 million. Tianjin TEDA Biomedical Engineering Company Limited has filed a Follow-on Equity Offering in the amount of HKD 63.441 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 239,400,000
Price\Range: HKD 0.265
Transaction Features: Subsequent Direct Listing Annonce • Oct 17
Tianjin TEDA Biomedical Engineering Company Limited Announces Supervisory Committee Changes Tianjin TEDA Biomedical Engineering Company Limited announced that Ms. Yang Chunyan has submitted her resignation to the Supervisory Committee due to her resignation from Tianjin TEDA Biomedical Engineering Company Limited (the "Company"). She has resigned as the Supervisor and Chairman of the Supervisory Committee, and her resignation will take effect on October 14, 2024. Ms. Yang has confirmed that she has no disagreement with the Board, and there is no other matter in respect of her resignation that needs to be brought to the attention of the shareholders of the Company. The resignation of the Resigning Supervisor will not result in the total number of the Supervisors falling below the statutory requirements under the relevant PRC laws and regulations and will not affect the operation of the Supervisory Committee. The Company will complete the election of Supervisor as soon as practicable in accordance with the Articles of Association and other relevant regulations. According to the requirements of the Articles, at the eighth meeting of the eighth session of the Supervisory Committee held on 15 October 2024, Ms. Liu Jinyu was elected as the Chairman of the eight session of the Supervisory Committee for a term to the date of expiry of the term of the eighth session of the Supervisory Committee. Reported Earnings • Aug 31
First half 2024 earnings released: CN¥0.002 loss per share (vs CN¥0.006 loss in 1H 2023) First half 2024 results: CN¥0.002 loss per share (improved from CN¥0.006 loss in 1H 2023). Revenue: CN¥211.6m (up 14% from 1H 2023). Net loss: CN¥4.12m (loss narrowed 63% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Annonce • Aug 15
Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2024 Results on Aug 30, 2024 Tianjin TEDA Biomedical Engineering Company Limited announced that they will report first half, 2024 results on Aug 30, 2024 Annonce • Jun 08
Tianjin Teda Biomedical Engineering Company Limited Appoints Mr. Tu Xiangzhen as the Independent Non-Executive Director Tianjin TEDA Biomedical Engineering Company Limited announced that at its AGM held on 7 June 2024, the shareholders approved the appointment of Mr. Tu Xiangzhen as the independent non-executive Director of the Company. Annonce • Apr 21
Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, Jun 07, 2024 Tianjin TEDA Biomedical Engineering Company Limited, Annual General Meeting, Jun 07, 2024, at 10:00 China Standard Time. Location: 9th Floor, Block A2, Tianda High-Tech Park, No. 80, The 4th Avenue, TEDA, Tainjin China Agenda: To consider and, if thought fit, approve the audited consolidated accounts of the Group for the year ended 31 December 2023; To consider and, if thought fit, approve the report of the directors of the Company; To consider and, if thought fit, approve the report of the Supervisory Committee of the Company; to consider and, if thought fit, approve the proposal of appointing Fan, Chan & Co. Limited as auditor of the Company for the financial year of 2024 and authorize the Directors of the Company to fix their remuneration; and to consider and, if thought fit, approve the appointment of Mr. Tu Xiangzhen as the independent non-executive Director of the Company; and to consider other matters. Reported Earnings • Mar 30
Full year 2023 earnings released: CN¥0.008 loss per share (vs CN¥0.015 loss in FY 2022) Full year 2023 results: CN¥0.008 loss per share (improved from CN¥0.015 loss in FY 2022). Revenue: CN¥398.0m (down 12% from FY 2022). Net loss: CN¥14.6m (loss narrowed 48% from FY 2022). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Annonce • Mar 26
Tianjin TEDA Biomedical Engineering Company Limited Announces Chief Executive Officer Changes Tianjin TEDA Biomedical Engineering Company Limited announced that Mr. Qin Wenhua resigned as the Joint CEO due to his busy schedule and his other business engagements with effect from 26 March 2024. Before Mr. Qin resigned as the Joint CEO, he and Ms. Sun Li jointly served as the Joint CEO. After Mr. Qin resigned as the joint CEO, Ms. Sun became the CEO of the Company. As Ms. Sun now serves as both the Chairman and the CEO, such practice deviates from code provision A.2.1 of the Code of Corporate Governance. The Board is of the opinion that it is appropriate and in the best interests of the Company for Ms. Sun to hold both positions as it helps to maintain the continuity of the policies and the stability of the operations of the Company. Annonce • Mar 13
Tianjin TEDA Biomedical Engineering Company Limited to Report Fiscal Year 2023 Final Results on Mar 28, 2024 Tianjin TEDA Biomedical Engineering Company Limited announced that they will report fiscal year 2023 final results on Mar 28, 2024 Reported Earnings • Nov 11
Third quarter 2023 earnings released: CN¥0.003 loss per share (vs CN¥0.004 loss in 3Q 2022) Third quarter 2023 results: CN¥0.003 loss per share (improved from CN¥0.004 loss in 3Q 2022). Revenue: CN¥119.3m (up 20% from 3Q 2022). Net loss: CN¥6.04m (loss narrowed 28% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Annonce • Oct 25
Tianjin TEDA Biomedical Engineering Company Limited to Report Q3, 2023 Results on Nov 09, 2023 Tianjin TEDA Biomedical Engineering Company Limited announced that they will report Q3, 2023 results on Nov 09, 2023 Reported Earnings • Aug 11
Second quarter 2023 earnings released: CN¥0.003 loss per share (vs CN¥0.004 loss in 2Q 2022) Second quarter 2023 results: CN¥0.003 loss per share (improved from CN¥0.004 loss in 2Q 2022). Revenue: CN¥99.5m (down 14% from 2Q 2022). Net loss: CN¥5.37m (loss narrowed 25% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Annonce • Jul 25
Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2023 Results on Aug 10, 2023 Tianjin TEDA Biomedical Engineering Company Limited announced that they will report first half, 2023 results on Aug 10, 2023 Reported Earnings • Apr 01
Full year 2022 earnings released: CN¥0.015 loss per share (vs CN¥0.022 loss in FY 2021) Full year 2022 results: CN¥0.015 loss per share (improved from CN¥0.022 loss in FY 2021). Revenue: CN¥449.7m (down 5.6% from FY 2021). Net loss: CN¥28.1m (loss narrowed 34% from FY 2021). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Non-Executive Director Yongkang Wang was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annonce • Nov 15
Tianjin TEDA Biomedical Engineering Company Limited Announces Mr. Hao Zhihui Will Retire as an Executive Director Tianjin TEDA Biomedical Engineering Company Limited announced Mr. Hao Zhihui will retire as an executive director at the EGM with effect from the conclusion of the EGM due to his retirement and will not offer himself for re-election. The number of members of the Board does not meet the requirements of the Company's Articles of Association as it has not yet identified a suitable candidate to succeed as an executive director. The Board will identify a suitable candidate to serve as an executive director as soon as practicable in order to comply with the requirements of the Company's Articles of Association. Reported Earnings • Nov 13
Third quarter 2022 earnings released: CN¥0.44 loss per share (vs CN¥0.001 profit in 3Q 2021) Third quarter 2022 results: CN¥0.44 loss per share (down from CN¥0.001 profit in 3Q 2021). Revenue: CN¥99.8m (down 14% from 3Q 2021). Net loss: CN¥8.38m (down CN¥9.39m from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Annonce • Oct 26
Tianjin TEDA Biomedical Engineering Company Limited to Report Nine Months, 2022 Results on Nov 10, 2022 Tianjin TEDA Biomedical Engineering Company Limited announced that they will report nine months, 2022 results on Nov 10, 2022 Annonce • Sep 07
Tianjin Teda Biomedical Engineering Company Limited Announces Executive Changes Tianjin TEDA Biomedical Engineering Company Limited (the Company) hereby announced that Mr. Qin Wenhua has been appointed as the Joint Chief Executive Officer of the Company and Ms. Sun Li has been re-designated as the Joint Chief Executive Officer of the Company from the Chief Executive Officer of the Company with effect from 6 September 2022. MR. QIN WENHUA Mr. Qin Wenhua (Mr. Qin), aged 56, graduated from Sun Yat-sen University in 1988 with a bachelor's degree in theoretical physics. Mr. Qin has 28 years of experience in business start-up. He has successively led and founded various fast-moving consumer goods companies such as Yunnan Red, Yunnan Shangri La Wine Industry, and Impression Wine Industry, all of which have developed into well-known brands in the industry. Mr. Qin has strategic framework capabilities in product design and positioning, brand marketing, consumer demand mining and service construction. Qin has successively established Jiangsu Weidi Electronic Trading Center Co. Ltd. Shanghai Yunyang Biotechnology Co. Ltd. Shanghai Meika Coffee Co. Ltd., Wisdom Cloud Drink Co. Ltd. Shanghai Weidi Network Technology Co. Ltd. other companies, and has experience in the implementation of and multiple consumer goods DTC projects. Ms. Sun Li (Ms. Sun), aged 49, holds a doctorate degree in Business Administration from the City University of Hong Kong and graduated from Central South University with a bachelor's degree in Technological Economics and with a master 's degree in Administration, respectively. Ms. Sun has engaged in investment banking for 15 years, and was among the first batch of sponsor representatives from the Securities Association of China in 2004. She is a member of Alxa SEE Conservation, an environmental protection charity organization for Chinese entrepreneurs. From May 2013 until now, Sun served as president, director and co-partner of Beijing Yingguxinye Investment Co. Ltd. In September 2014, she was the founding member of Tianjin Teda Wings of the Angel. Investor Club. From May 2015 until now, Sun was appointed as supervisors of Shenzhen Xiangyong Investment Company Limited and Dongguan Lvye Fertilisers Company Limited. From September 2015 until now, Sun, as the beneficial owner of Beijing Tianyuhongtai Technology Co. Ltd. held its 16% shares. From December 2015 until now, she was appointed as a director of Beijing Yingguchuangrong Information Technology Co. Ltd. From August 2015 until now, Ms. Sun was appointed as an executive director and the Chairman. of the Board of the Company. From September 2015 to January 2019 and from 30 December 2019, Ms. Sun concurrently serves Officer of the Company. Reported Earnings • Aug 10
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: CN¥116.0m (down 1.2% from 2Q 2021). Net loss: CN¥7.20m (down CN¥8.18m from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Annonce • Jul 23
Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2022 Results on Aug 09, 2022 Tianjin TEDA Biomedical Engineering Company Limited announced that they will report first half, 2022 results on Aug 09, 2022 Annonce • Jul 19
Tianjin TEDA Biomedical Engineering Company Limited (SEHK:8189) entered into the Equity Transfer Agreement to acquire Shanghai Weidi Network Technology Company from three shareholders for CNY12.8 million. Tianjin TEDA Biomedical Engineering Company Limited (SEHK:8189) entered into the Equity Transfer Agreement to acquire Shanghai Weidi Network Technology Company from three shareholders for CNY12.8 million on July 18, 2022. The net asset value of Shanghai Weidi as of 30 June 2022 was RMB13.1 million. Reported Earnings • May 11
First quarter 2022 earnings released: CN¥0.003 loss per share (vs CN¥0 in 1Q 2021) First quarter 2022 results: CN¥0.003 loss per share (down from CN¥0 in 1Q 2021). Revenue: CN¥89.2m (down 28% from 1Q 2021). Net loss: CN¥6.04m (loss widened CN¥5.88m from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Non-Executive Director Yongkang Wang was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annonce • Apr 23
Tianjin TEDA Biomedical Engineering Company Limited to Report Q1, 2022 Results on May 10, 2022 Tianjin TEDA Biomedical Engineering Company Limited announced that they will report Q1, 2022 results on May 10, 2022 Reported Earnings • Apr 03
Full year 2021 earnings released Full year 2021 results: Revenue: CN¥476.4m (up 29% from FY 2020). Net loss: CN¥42.3m (loss narrowed 12% from FY 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Annonce • Feb 09
Tianjin TEDA Biomedical Engineering Company Limited Approves Appointment of Mr. Zhao Zhiyou as the Independent Supervisor Tianjin TEDA Biomedical Engineering Company Limited announced that at its special general meeting held on February 8, 2022, shareholders approved the appointment of Mr. Zhao Zhiyou as the independent supervisor of the company for a term commencing from the date of passing this resolution and ending upon the conclusion of the seventh session of the Supervisory Committee. Reported Earnings • Nov 11
Third quarter 2021 earnings released: EPS CN¥0.001 (vs CN¥0.006 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥115.4m (up 34% from 3Q 2020). Net income: CN¥1.01m (up CN¥11.7m from 3Q 2020). Profit margin: 0.9% (up from net loss in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 10
Second quarter 2021 earnings released The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥117.4m (up 21% from 2Q 2020). Net income: CN¥975.2k (up 200% from 2Q 2020). Profit margin: 0.8% (up from 0.3% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Executive Departure • Apr 02
Non-Executive Director has left the company On the 26th of March, Li Gai's tenure as Non-Executive Director ended after 2.5 years in the role. We don't have any record of a personal shareholding under Li's name. Li is the only executive to leave the company over the last 12 months. Reported Earnings • Mar 28
Full year 2020 earnings released: CN¥0.025 loss per share (vs CN¥0.045 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CN¥369.4m (up 3.0% from FY 2019). Net loss: CN¥48.0m (loss narrowed 43% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings. Annonce • Mar 09
Tianjin TEDA Biomedical Engineering Company Limited to Report Fiscal Year 2020 Results on Mar 24, 2021 Tianjin TEDA Biomedical Engineering Company Limited announced that they will report fiscal year 2020 results on Mar 24, 2021 Annonce • Oct 28
Tianjin TEDA Biomedical Engineering Company Limited to Report Q3, 2020 Results on Nov 10, 2020 Tianjin TEDA Biomedical Engineering Company Limited announced that they will report Q3, 2020 results on Nov 10, 2020 Annonce • Jul 25
Tianjin TEDA Biomedical Engineering Company Limited to Report First Half, 2020 Results on Aug 10, 2020 Tianjin TEDA Biomedical Engineering Company Limited announced that they will report first half, 2020 results on Aug 10, 2020 
